Clinical Trials

The clinical trials listed below are for informational purposes only and are not endorsed by the AST. More information on clinical trials can be found in our clinical trials brochure. For information about posting a clinical trial, contact JoAnn Gwynn at jgwynn@myast.org.

Clinical Trials for Kidney Recipients

• Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
  Sponsor: Atara Biotherapeutics
  Organ Type: All organs
  Ages Accepted: All ages
  Genders Accepted: Both male and female
  Expected Study Completion Date: Monday, November 30, 2020
  Other Requirements
  COVID-19 Update: The ALLELE trial remains open and is currently enrolling patients. Please visit clinicaltrials.gov for information regarding sites and investigators.
   
• Interleukin 6 blockade Modifying Antibody mediated Graft INjury and eGFR decline (IMAGINE)
  Sponsor: CSL Behring
  Organ Type: Kidney
  Ages Accepted: 18 years old to 70 years old
  Genders Accepted: Both male and female
  Expected Study Completion Date: April 2028
   
• A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants
  Sponsor: Medeor Therapeutics, Inc.
  Organ Type: Kidney
  Ages Accepted: Age ≥18 and ≤70 years
  Genders Accepted: Both male and female
  Expected Study Completion Date: January 2022
   
• A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)
  Sponsor: Novartis 
  Organ Type: Kidney
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date: July 28, 2026

• A Randomized, Controlled, Multi-center, Safety and Efficacy Study of FCR001 Cell-based Therapy Relative to a Tacrolimus and Mycophenolate-based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1)
  Sponsor: Talaris Therapeutics
  Organ Type: Living Donor Kidney
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date: April 30, 2025

   

Clinical Trials for Other Organ Types

• Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
  Sponsor: Atara Biotherapeutics
  Organ Type: All organs
  Ages Accepted: All ages
  Genders Accepted: Both male and female
  Expected Study Completion Date: Monday, November 30, 2020
  Other Requirements
  COVID-19 Update: The ALLELE trial remains open and is currently enrolling patients. Please visit clinicaltrials.gov for information regarding sites and investigators.
   
• A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
  Sponsor: Takeda Pharmaceutical Company Limited
  Organ Type: Hematopoietic Stem Cell Transplant
  Ages Accepted: ≥16 years of age
  Genders Accepted: Both male and female
  Expected Study Completion Date: Tuesday, August 13, 2021
  Other Requirements
  
   
• A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of an Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-month Additional Follow-up (CONTRAIL I)
  Sponsor: Novartis 
  Organ Type: Liver
  Ages Accepted: 18 years to 70 years 
  Genders Accepted: Both male and female
  Expected Study Completion Date: April 26, 2023